Latest California Healthline Stories
Kaiser Health News’ Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors. The problems they found at the company’s main U.S. drug-testing laboratory in Foster City, Calif., were so bad, they recommended withholding approval.
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
Manufacturers of lucrative drugs say they’re offering discounts off the high sticker prices ― but taxpayers footing the big bills might never know what the state is paying or if it’s getting a good deal.
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.